deferasirox 500 MG Tablet for Oral Suspension [Exjade]
deferasirox
RxCUI: 616163
What the CMS Formulary Data Shows for deferasirox 500 MG Tablet for Oral Suspension [Exjade]
Per the CMS 2026 Part D formulary file, deferasirox 500 MG Tablet for Oral Suspension [Exjade] (RxNorm concept RXCUI 616163, generic name deferasirox) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to deferasirox 500 MG Tablet for Oral Suspension [Exjade] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 3,436 Part D beneficiaries filled deferasirox 500 MG Tablet for Oral Suspension [Exjade] in 2023, with total plan-and-beneficiary spending of $49,214,658 and an average per-beneficiary annual cost of $14,323.24. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry deferasirox 500 MG Tablet for Oral Suspension [Exjade] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 3,436
- Total spending
- $49,214,658
- Avg per beneficiary
- $14,323.24
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering deferasirox 500 MG Tablet for Oral Suspension [Exjade]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $34.50 | NY |
Frequently Asked Questions
Is deferasirox 500 MG Tablet for Oral Suspension [Exjade] covered by Medicare Part D?
Yes, deferasirox 500 MG Tablet for Oral Suspension [Exjade] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is deferasirox 500 MG Tablet for Oral Suspension [Exjade] on Medicare Part D plans?
deferasirox 500 MG Tablet for Oral Suspension [Exjade] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does deferasirox 500 MG Tablet for Oral Suspension [Exjade] require prior authorization?
100% of Part D formularies require prior authorization for deferasirox 500 MG Tablet for Oral Suspension [Exjade]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on deferasirox 500 MG Tablet for Oral Suspension [Exjade]?
In 2023, total Medicare Part D spending on deferasirox 500 MG Tablet for Oral Suspension [Exjade] was $49,214,658, covering 3,436 beneficiaries. The average spend per beneficiary was $14,323.24.
Read our methodology - how this data is sourced, computed, and verified.